02660nas a2200385   4500000000100000008004100001100001300042700001500055700001400070700001400084700001200098700001300110700001900123700001200142700001500154700001500169700001700184700001500201700001200216700001500228700001400243700001500257700001900272700001400291700001900305700001700324700001500341700001800356245023800374250001500612300001200627490000800639520157600647020005102223       2015                            d1 aSelak V.1 aCrengle S.1 aRafter N.1 aBullen C.1 aThom S.1 aBrown A.1 aPrabhakaran D.1 aBots M.1 aPoulter N.1 aGrobbee D.1 aUsherwood T.1 aWebster R.1 aCass A.1 aStanton A.1 aWadham A.1 aStepien S.1 aC. Elley Raina1 aRodgers A1 aBillot Laurent1 aPeiris David1 aNeal Bruce1 aPatel Anushka00aEffectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries  a2016/01/07  a147-1560 v2053 a<p>
AIMS: To conduct a prospective, individual participant data (IPD) meta-analysis of randomised controlled trials comparing a polypill-based approach with usual care in high risk individuals. METHODS AND RESULTS: Three trials comparing polypill-based care with usual care in individuals with CVD or high calculated cardiovascular risk contributed IPD. Primary outcomes were self-reported adherence to combination therapy (anti-platelet, statin and &gt;/=two blood pressure (BP) lowering agents), and difference in mean systolic BP (SBP) and LDL-cholesterol at 12months. Analyses used random effects models. Among 3140 patients from Australia, England, India, Ireland, New Zealand and The Netherlands (75% male, mean age 62years), median follow-up was 15months. At baseline, 84%, 87% and 61% respectively were taking a statin, anti-platelet agent and at least two BP lowering agents. At 12months, compared to usual care, participants in the polypill arm had higher adherence to combination therapy (80% vs. 50%, RR 1.58; 95% CI, 1.32 to 1.90; p&lt;0.001), lower SBP (-2.5mmHg; 95% CI, -4.5 to -0.4; p=0.02) and lower LDL-cholesterol (-0.1mmol/L; 95% CI, -0.2 to 0.0; p=0.04). Baseline treatment levels were a major effect modifier for adherence and SBP (p-homog &lt;0.0001 and 0.02 respectively) with greatest improvements seen among those under-treated at baseline. CONCLUSIONS: Polypill therapy significantly improved adherence, SBP and LDL-cholesterol in high risk patients compared with usual care, especially among those who were under-treated at baseline.
</p>
  a1874-1754 (Electronic)<br/>0167-5273 (Linking)